• PCSK9 Gene Editing and the Logic of Prevention

    PCSK9 Gene Editing and the Logic of Prevention

    PCSK9 gene editing reaches beyond ordinary cholesterol treatment by changing the liver’s instructions for producing PCSK9. This reflective essay explains LDL receptor recycling, base editing, cumulative cholesterol exposure, and the promise of one-time therapy. It also examines the responsibility that comes with permanent biological change, balancing scientific innovation with the careful evidence, patient selection, and long-term monitoring that such powerful treatment requires before clinical use.

    Categorized as , , ,
  • LDL Below 55: Better Protection After Cardiovascular Disease

    LDL Below 55: Better Protection After Cardiovascular Disease

    Ez-PAVE directly compared LDL cholesterol targets below 55 and 70 mg/dL in adults with established atherosclerotic cardiovascular disease. Over three years, intensive targeting reduced the primary cardiovascular outcome from 9.7% to 6.6%, mainly through fewer heart attacks and revascularization procedures. The trial strengthens the case for lower LDL goals in secondary prevention while showing a broadly similar safety profile between treatment strategies in this population.

    Categorized as , , ,